Exozymes annual return on equity
2023
2024
2025
Exozymes Return on Equity (ROE) Growth & History (EXOZ)
Exozymes's return on equity was −132.56% for fiscal 2025.
View full Exozymes company overviewExozymes annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −132.56% | −15.76 pp |
| 2024 | 2024-12-31 | −116.80% | +295.74 pp |
| 2023 | 2023-12-31 | −412.54% | — |
Exozymes quarterly return on equity
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −111.10% | −81.81 pp |
| Q1 2026 | 2026-03-31 | −96.25% | −77.01 pp |
| Q4 2025 | 2025-12-31 | −60.54% | −6.69 pp |
| Q3 2025 | 2025-09-30 | −36.27% | — |
| Q2 2025 | 2025-06-30 | −29.29% | — |
| Q1 2025 | 2025-03-31 | −19.24% | — |
| Q4 2024 | 2024-12-31 | −53.85% | — |
Exozymes return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Exozymes's return on equity increased from −412.54% to −132.56%, a change of +279.98 percentage points. The latest reported quarter, Q2 2026, shows −111.10%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Exozymes source filings ↗Community posts
eXoZymes selects Curia to scale up its NCT manufacturing process
eXoZymes ($EXOZ) entered an agreement with contract manufacturer Curia to transfer and scale its NCT production process. Work will take place at Curia facilities in Spain and Italy, covering enzyme production, the cell-free reaction and pro ...